PALI Palisade Bio
- 6.4383
- -0.0217-0.34%
Palisade Bio News
Buy Rating Affirmed for Palisade Bio's PALI-2108 Amid Strong Financials and Promising Partnership
Palisade Bio Q1 EPS $(4.59) Misses $(4.28) Estimate
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(4.59) per share which missed the analyst consensus estimate of $(4.28) by 7.24 percent. This is a 43.54 percent increase over losses of $(8.13
Palisade Bio 1Q Loss/Shr $4.59 >PALI
Palisade Bio 1Q Loss/Shr $4.59 >PALI
Palisade Bio 1Q Research and Development Expenses $2.2M >PALI
Palisade Bio 1Q Research and Development Expenses $2.2M >PALI
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end– Sufficient cash on hand to execute on bu
Palisade Bio | 10-Q: Quarterly report
Palisade Bio Welcomes New Board Member, Eyes Strategic Growth
Palisade Bio Appoints Margery Fischbein to Its Board of Directors
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globallyCarlsbad, CA, May 07, 2024 — Pal
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,
12 Health Care Stocks Moving In Friday's After-Market Session
GainersNeuBase Therapeutics (NASDAQ:NBSE) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. Aptevo Therapeutics (
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 02, 2024 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue guidance for the second quarter.AMD guided
SYT and STI Among Mid-day Movers
Maxim Group: Reiterates Palisade Bio (PALI.US) rating, adjusted from buy to buy rating, target price of $22.50.
Maxim Group: Reiterates Palisade Bio (PALI.US) rating, adjusted from buy to buy rating, target price of $22.50.
Maxim Group Reiterates Buy on Palisade Bio, Maintains $22.5 Price Target
Maxim Group analyst Naz Rahman reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $22.5 price target.
Palisade Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 204.84% Maxim Group → $22.5 Reiterates Buy → Buy 04/16/2024 204.84% Maxim Group $22.5 → $22.5 M
Decoding The Surge: Palisade Bio (PALI) Shares On The Move
The current trading session has witnessed a notable surge in the shares of Palisade Bio, Inc. (NASDAQ: PALI), with an impressive increase of 21.46%, elevating its value to $7.32. This substantial uptick in PALI stock price follows the successful completion of an analysis for the development of a new drug. Today, Palisade Bio (PALI) has ...
US Stocks Mixed; Amazon Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 0.1% on Wednesday.Following the market opening Wednesday, the Dow traded up 0.09% to 37,851.28 while the NASDAQ rose 0.04% to 1
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts
US stocks look set to open modestly lower in Wednesday's trading session despite better-than-expected private employment figures, as investors anxiously await the Federal Reserve's rate policy decisio
Palisade Bio Stock Rallies 50% Premarket on Colitis Drug Update
Analysis
Price Target
No Data
